Soligenix Inc. (NASDAQ: SNGX) announced positive top-line results from its Phase 2a proof-of-concept clinical trial evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s disease. The findings, highlighted in a recent article, underscore the potential of this novel innate defense regulator to modulate immune response rather than broadly suppress it, offering a differentiated approach for patients with limited treatment options.
Behçet’s disease is a rare, chronic inflammatory condition characterized by recurrent and painful oral and genital ulcers, eye inflammation, and systemic complications that significantly impair quality of life. Available treatments are often inconsistent and may involve immunosuppressive therapies that increase infection risk. Clinical trial updates in this area are particularly important due to the high unmet need.
SGX945 is designed to harness the body’s innate immune system by reducing harmful inflammation while preserving the ability to fight infections. In the Phase 2 study, SGX945 was reported to be safe and well tolerated, a critical factor for a chronic disease requiring repeated or long-term treatment. The trial results represent a notable step forward in improving care for patients with this underserved condition.
The full article detailing these findings can be accessed at https://nnw.fm/jUGkJ.
Soligenix is a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs. Its Specialized BioTherapeutics segment is developing HyBryte™ (SGX301) for cutaneous T-cell lymphoma, with regulatory submissions planned after successful Phase 3 trials. The segment also includes expansion of synthetic hypericin into psoriasis and further development of dusquetide for oral mucositis and Behçet’s disease.
The company’s Public Health Solutions segment includes vaccine programs for ricin toxin (RiVax®), filoviruses, and COVID-19 (CiVax™), utilizing its proprietary ThermoVax® heat stabilization platform. These programs have been supported by government grants from NIAID, DTRA, and BARDA.
For more information about Soligenix and its pipeline, visit www.Soligenix.com. The latest news and updates on SNGX are available at https://nnw.fm/SNGX.
